Crossmark Global Holdings Inc. Raises Position in Chemours Co (CC)

Share on StockTwits

Crossmark Global Holdings Inc. boosted its position in shares of Chemours Co (NYSE:CC) by 13.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,540 shares of the specialty chemicals company’s stock after acquiring an additional 2,620 shares during the period. Crossmark Global Holdings Inc.’s holdings in Chemours were worth $636,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Xact Kapitalforvaltning AB grew its stake in shares of Chemours by 59.7% in the 4th quarter. Xact Kapitalforvaltning AB now owns 27,815 shares of the specialty chemicals company’s stock valued at $785,000 after purchasing an additional 10,400 shares during the period. Exane Derivatives acquired a new position in shares of Chemours in the 4th quarter worth approximately $3,777,000. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its holdings in shares of Chemours by 41.9% in the 4th quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 90,434 shares of the specialty chemicals company’s stock worth $2,552,000 after acquiring an additional 26,700 shares in the last quarter. FUKOKU MUTUAL LIFE INSURANCE Co boosted its holdings in shares of Chemours by 357.1% in the 4th quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 3,200 shares of the specialty chemicals company’s stock worth $90,000 after acquiring an additional 2,500 shares in the last quarter. Finally, Advisor Partners LLC boosted its holdings in shares of Chemours by 13.8% in the 4th quarter. Advisor Partners LLC now owns 8,362 shares of the specialty chemicals company’s stock worth $236,000 after acquiring an additional 1,014 shares in the last quarter. Hedge funds and other institutional investors own 80.16% of the company’s stock.

NYSE:CC opened at $38.75 on Thursday. Chemours Co has a 52-week low of $25.17 and a 52-week high of $53.25. The company has a debt-to-equity ratio of 3.48, a quick ratio of 1.39 and a current ratio of 2.03. The firm has a market cap of $6.59 billion, a price-to-earnings ratio of 10.14, a PEG ratio of 0.43 and a beta of 2.32.

CC has been the topic of several recent analyst reports. Citigroup raised Chemours from a “neutral” rating to a “buy” rating in a report on Friday, January 4th. HSBC initiated coverage on Chemours in a report on Tuesday, January 8th. They issued a “buy” rating and a $52.00 target price on the stock. Barclays reissued a “buy” rating and issued a $48.00 target price on shares of Chemours in a report on Tuesday, January 15th. BMO Capital Markets reduced their target price on Chemours from $68.00 to $58.00 and set an “outperform” rating on the stock in a report on Monday, November 5th. They noted that the move was a valuation call. Finally, Zacks Investment Research raised Chemours from a “sell” rating to a “hold” rating in a report on Tuesday, December 11th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $49.22.

In other news, Director Richard H. Brown acquired 10,000 shares of Chemours stock in a transaction on Monday, December 3rd. The shares were purchased at an average price of $28.60 per share, with a total value of $286,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 1.75% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION WARNING: “Crossmark Global Holdings Inc. Raises Position in Chemours Co (CC)” was originally published by BBNS and is the sole property of of BBNS. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://baseballnewssource.com/2019/02/14/crossmark-global-holdings-inc-raises-position-in-chemours-co-cc/3214918.html.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.

Featured Story: Institutional Investors

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemours Co (NYSE:CC).

Institutional Ownership by Quarter for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.